Ionis Invests For The Future In New Technologies, Manufacturing Innovation
Antisense Pioneer Looks Beyond Brain, Heart And RNA
Through partnerships with Bicycle and Metagenomi, Ionis is working on new chemistries and novel medicines. It is also expanding manufacturing capacity to enable its scientific growth.
You may also be interested in...
The US firm has sold some of its royalty stream for the gene therapy Spinraza and cardiovascular drug candidate, pelacarsen, to Royalty Pharma for $500m upfront, which should help fund upcoming milestones for Ionis’ late-stage pipeline.
Ionis will pay $80m up front to Metagenomi to access its next-generation gene-editing technology to jointly research new therapies for up to four genetic targets.
Small-molecule drug delivery tech could help Ionis deliver its oligonucleotides where others cannot reach.